Results 41 to 50 of about 42,293 (268)

Octreotide may improve pharyngocutaneous fistula healing through downregulation of cystatins: A pilot study

Laryngoscope Investigative Otolaryngology, 2023
Background Pharyngocutaneous fistula (PCF) and salivary leaks are well known complications of head and neck surgery. The medical management of PCF has included the use of octreotide without a well‐defined understanding of its therapeutic mechanism.
Jonathan Cohen, William Reed, Matthew W. Foster, Russel R. Kahmke, Daniel J. Rocke, Liana Puscas, Trinitia Y. Cannon, Walter T. Lee   +7 more
doaj   +1 more source

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors [PDF]

, 2018
Background. Neuroendocrine tumors (NETs) are characterized by having behavior and prognosis that depend upon tumor histology, primary site, staging, and proliferative index.
Baldelli, Roberto, Campana, Davide, Di Giacinto, Paola, Isidori, Andrea, Lania, Andrea, Lenzi, Andrea, Rizza, Laura, Rota, Francesca, Zuppi, Paolo   +8 more
core   +1 more source

Octreotide-induced thrombocytopenia: a case report

Journal of Medical Case Reports, 2011
Introduction Thrombocytopenia is an extremely rare complication of octreotide therapy and can be life threatening in the setting of esophageal variceal bleeding.
Rizvi Nahid, Rashidi Armin
doaj   +1 more source

Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor. [PDF]

, 2012
Pancreatic neuroendocrine tumors (PNETs) are relatively rare tumors that arise in the endocrine cells of the pancreas. Historically, somatostatin analogues have been used in this disease primarily for symptom control and, to a limited extent, disease ...
Devata, Sumana, Kim, Edward J
core   +2 more sources

Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature

Case Reports in Gastrointestinal Medicine, 2019
We report a patient with multiple endocrine neoplasia type 1 with pancreatic polypeptide (PP) secreting subcentimeter pancreatic neuroendocrine tumors (pNETs) treated with octreotide and review the current literature that pertains to the management of ...
Matthew H. Kemm, Cory D. Manly, Thanh D. Hoang, Vinh Q. Mai, Mohamed K. M. Shakir   +4 more
doaj   +1 more source

Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1

Cellular Physiology and Biochemistry, 2018
Background/Aims: Hepatocellular carcinoma (HCC) is a major threat to human health. The condition carries a high risk of death; 45% of new cases occur in China.
Chuan-Zhong Huang, Ai-Min Huang, Jing-Feng Liu, Bin Wang, Ke-Can Lin, Yun-Bin Ye   +5 more
doaj   +1 more source

Pasireotide for the Medical Management of Feline Hypersomatotropism [PDF]

, 2015
BACKGROUND: Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST.
Abraham, Adams, Alt, Appleton, Bhayana, Bruns, Castillo, Church, Colao, Colao, Cuevas-Ramos, Fedele, Fernandez-Rodriguez, Fougner, Golor, Henry, Hofland, Juul, Katznelson, Kvols, Lamb, Lamberts, Maxwell, Meij, Miller, Murray, Myers, Niessen, Niessen, Niessen, Niessen, Petrus, Polska, Rand, Ray, Schmid, Schmid, Sheppard, Slingerland, Sohmiya, Starkey, Stolk, Taboada, Wajchenberg, Zatelli, Zou   +45 more
core   +1 more source

Automated GMP compliant production of [18F]AlF-NOTA-octreotide

EJNMMI Radiopharmacy and Chemistry, 2020
Background Gallium-68 labeled synthetic somatostatin analogs for PET/CT imaging are the current gold standard for somatostatin receptor imaging in neuroendocrine tumor patients.
Térence Tshibangu, Christopher Cawthorne, Kim Serdons, Elin Pauwels, Willy Gsell, Guy Bormans, Christophe M. Deroose, Frederik Cleeren   +7 more
doaj   +1 more source

Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism [PDF]

, 2017
BACKGROUND: Long‐term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel somatostatin analogue, decreases serum insulin‐like growth factor 1 (IGF‐1) and improves insulin sensitivity in cats with HS when ...
Abraham, Berg, Bruns, Church, Colao, Colao, Combes, Cozzi, Dowling, Dunning, Feelders, Freda, Gadelha, Henry, Hofland, Hubina, Hussaini, Jaffe, Katznelson, Kurosaki, Lamb, Laron, Ma, Meij, Meij, Myers, Niessen, Niessen, Niessen, Patel, Petersenn, Peterson, Reubi, Reusch, Reusch, Sathyapalan, Schaefer, Scudder, Shanik, Slingerland, Slingerland, Theodoropoulou, Tyson, Zambre   +43 more
core   +2 more sources

Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis [PDF]

, 2007
Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction,1 as well as in patients with acute liver failure.2 In spite of its
Angeli P, Arroyo V, BERNARDI, MAURO, Blendis L, Di Bona G, Garcia Tsao G, Gerbes A, Ginès P, Guevara M, Gülberg V, Henriksen JH, Kamath P, Lee S, Moore K, Moreau R, Mullen K, Ortega R, Ruiz del Arbol L, Salerno F, Sanyal A, Terg R., Wong F   +21 more
core   +4 more sources